The aim of this study was to describe clinical, imaging, and laboratory features of acute
pulmonary embolism (APE) in patients with
COVID-19 associated
pneumonia. Patients with
COVID-19 associated
pneumonia who underwent a computed tomography pulmonary artery (
CTPA) scan for suspected APE were retrospectively studied. Laboratory data and
CTPA images were collected. Imaging characteristics were analyzed descriptively. Laboratory data were analyzed and compared between patients with and without APE. A series of 25
COVID-19 patients who underwent
CTPA between January 2020 and February 2020 were enrolled. The median
D-dimer level founded in these 25 patients was 6.06 μg/mL (interquartile range [IQR] 1.90-14.31 μg/mL). Ten (40%) patients with APE had a significantly higher level of
D-dimer (median, 11.07 μg/mL; IQR, 7.12-21.66 vs median, 2.44 μg/mL; IQR, 1.68-8.34, respectively, P = .003), compared with the 15 (60%) patients without APE. No significant differences in other laboratory data were found between patients with and without APE. Among the 10 patients with APE, 6 (60%) had a bilateral
pulmonary embolism, while 4 had a unilateral
embolism. The
thrombus-prone sites were the right lower lobe (70%), the left upper lobe (60%), both upper lobe (40%) and the right middle lobe (20%). The
thrombus was partially or completely absorbed after
anticoagulant therapy in 3 patients who underwent a follow-up
CTPA. Patients with
COVID-19 associated
pneumonia have a risk of developing APE during the disease. When the
D-dimer level abnormally increases in patients with
COVID-19 pneumonia,
CTPA should be performed to detect and assess the severity of APE.